Highest-materiality recent filing
Galera Therapeutics announces 1-for-200 reverse stock split effective July 12, 2026
Reverse stock split at 1:200 ratio; effective July 12, 2026 at 11:59 p.m. ET.
Galera Therapeutics converts all Series B Preferred Stock into 42.8M common shares
Converted 42,839.11 Series B preferred shares into 42,839,103 common shares on May 15, 2026.
Galera Therapeutics doubles authorized common stock to 400M shares; adds written consent right
Authorized common stock increased from 200M to 400M shares via charter amendment filed May 11, 2026.
Galera shareholders approve reverse split (1:75 to 1:200) and share increase to 400M
Elected J. Mel Sorensen (Class III), Nancy Chang and Michael Friedman (Class I) as directors.
Galera Therapeutics to merge with Obsidian in all-stock deal backed by $350M PIPE
Galera and Obsidian to merge under new parent; Galera shareholders get ~1.8% of combined co plus CVRs.
Galera converts 76.5K Series B preferred into 76.5M common shares; warrants exercised
Converted 76,479.175 Series B Preferred shares into 76,479,164 common shares on April 7, 2026.
Galera Therapeutics schedules 2025/2026 Annual Meeting for May 8, 2026
Stockholder proposal/nomination deadline set for April 13, 2026.
On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.
Galera Therapeutics enters retention bonus agreement with CAO Joel Sussman for up to $250,000
Up to $250,000 in retention bonuses tied to timely completion and filing of reporting obligations.
Galera Therapeutics sells avasopasem and rucosopasem assets to Biossil Inc.
Sold all dismutase mimetic assets including avasopasem (GC4419) and rucosopasem (GC4711) to Biossil Inc., a Canadian company.
Galera sells avasopasem/rucosopasem assets to Biossil for $3.5M upfront, up to $105M milestones
Biossil Inc. acquires all of Galera's dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711).
Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products
Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.
Galera extends registration statement filing deadline to June 30, 2025
Amendment to Registration Rights Agreement dated Dec 30, 2024 extends Filing Deadline by 180 days from Closing Date.
Acquisition of Nova Pharmaceuticals closed on Dec 30, 2024, via merger agreement.
Galera Therapeutics stockholders elect two Class II directors and ratify KPMG as auditor
Lawrence Alleva elected with 27,501,778 votes for, 3,359,405 withheld, 10,682,973 broker non-votes.
Acquisition closed Dec 30; Galera issued 119,318 shares of Series B Non-Voting Convertible Preferred (1,000-to-1 conversion).
Galera Therapeutics schedules 2024 annual meeting for Feb 24, 2025; sets proposal deadline Dec 30
Annual meeting set for February 24, 2025; deadline for stockholder proposals and director nominations is December 30, 2024.
Galera Therapeutics shareholders reject liquidation and dissolution plan
Proposal to approve dissolution received 13,938,893 FOR and 18,075,579 AGAINST; not approved.
Galera Therapeutics gets Nasdaq delisting notice; stock to be delisted mid-September
Nasdaq notified Galera on Aug 31, 2024; will file Form 25 on Sept 4 to delist common stock.
Galera Therapeutics board approves dissolution; CFO and CLO positions eliminated
Board unanimously approved Plan of Liquidation and Dissolution; special stockholder meeting on or around Oct 17, 2024.
Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000
Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.
Galera Therapeutics eliminates COO role; stock moves to OTC Pink
COO Robert Beardsley's position eliminated June 4, 2024 to reduce costs.
Galera Therapeutics receives Nasdaq delisting notice; trading to suspend June 4
Notice from Nasdaq on May 31, 2024 for failure to meet minimum market value, bid price, and publicly held shares requirements.
Galera Q1 net loss narrows to $4.4M; ceases clinical development, explores strategic alternatives
Net loss of $4.4M ($0.08/sh) vs $17.7M ($0.50/sh) in Q1 2023; R&D expenses fell to $1.5M.
Galera Therapeutics adopts limited-duration poison pill after recent stock accumulations
Board adopted Rights Agreement effective May 2, 2024, responding to recent accumulations of common stock.
FY2023 net loss $59.1M ($1.33/sh); Q4 net loss $5.6M ($0.10/sh); cash $18.3M as of Dec 31, 2023.
Galera Therapeutics receives Nasdaq delisting notices; plans to appeal
March 21 notice: failed to meet $50M MVLS and $1.00 bid price for 30 consecutive days.
Galera Therapeutics reports Q3 loss; FDA requires new avasopasem trial; GRECO trials halted
FDA issued Complete Response Letter for avasopasem NDA; requires an additional Phase 3 trial for resubmission.
Galera: FDA demands new Phase 3 for avasopasem; GRECO-2 futility halts both rucosopasem trials
FDA reiterated need for an additional Phase 3 trial of avasopasem for radiotherapy-induced SOM.
Galera Therapeutics receives Nasdaq delisting notice for MVPHS non-compliance
Nasdaq notified Galera on Sep 25, 2023 that MVPHS fell below $15M required for Global Market listing.
Galera Therapeutics receives Nasdaq delisting notices for MVLS and bid price deficiencies
Notices: MVLS below $50M and bid price below $1.00 for 30 consecutive business days.
Galera receives FDA CRL for avasopasem, cuts workforce 70%, Q2 net loss $20.7M
FDA issued Complete Response Letter for avasopasem NDA; additional clinical trial required for resubmission.
Galera Therapeutics receives FDA CRL for avasopasem; cuts workforce by 70% to extend cash runway
FDA issued CRL for avasopasem NDA; Phase 3 ROMAN + GT-201 data not sufficiently persuasive; additional trial required.
Galera Therapeutics shareholders elect two Class I directors, ratify KPMG
Michael Powell, Ph.D. elected with 15,141,283 votes for (76.2% of votes cast).
Galera Therapeutics sues CROs over Phase 3 ROMAN trial statistical error
Filed lawsuit in Pennsylvania against Alira Health Clinical and IQVIA Biotech for breach of contract and negligence.
Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9
Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.
Galera Therapeutics discloses no exposure to Silicon Valley Bank failure
Company confirms it holds no cash deposits or securities with SVB.
Galera reports FY2022 net loss $62.2M; avasopasem NDA priority review, PDUFA Aug 9, 2023
Q4 2022 net loss of $16.2M ($0.58 per share); FY2022 net loss $62.2M ($2.30 per share).
Galera raises $30M in registered direct offering of stock and warrants
Offering of 14,320,000 shares at $2.095/share plus warrants to buy 14,320,000 shares at $1.97.
FDA accepted NDA for avasopasem manganese for radiotherapy-induced severe oral mucositis in head/neck cancer.
Galera Therapeutics regains compliance with Nasdaq MVLS requirement, delisting avoided
Received Nasdaq letter confirming compliance with $50M MVLS requirement for continued listing on Nasdaq Global Market.
Galera submits NDA for avasopasem to reduce severe oral mucositis in head & neck cancer
NDA for avasopasem submitted to FDA for radiotherapy-induced severe oral mucositis (SOM) in head/neck cancer.
Galera receives Nasdaq delisting notice for failing to meet $50M MVLS; plans appeal
Nasdaq notified Galera on Dec 6, 2022 of failure to regain compliance with $50M MVLS requirement by Dec 5 deadline.
Galera reports Q3 net loss $16M; avasopasem NDA on track by year-end
Net loss of $16M ($0.60/share) vs $22.6M ($0.86) in Q3 2021; cash $42.8M.
One-year follow-up: avasopasem maintained comparable tumor outcomes and overall survival vs placebo in HNC patients.
Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022
Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.
Galera Therapeutics stockholders elect two Class III directors, ratify KPMG as auditor
Dr. Emmett Cunningham and Dr. J. Mel Sorensen elected as Class III directors with ~10.6M and ~10.7M votes for, respectively.
Galera Therapeutics receives Nasdaq delisting notice for failure to meet $50M MVLS requirement
Received Nasdaq notice on June 8, 2022 for non-compliance with minimum Market Value of Listed Securities of $50M.
Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022
Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.
Galera Q4/2021 net loss $16.8M; positive Phase 3 ROMAN trial, cash $71M
Net loss of $16.8M ($0.64/sh) in Q4 2021 vs $20.1M ($0.80/sh) in Q4 2020; FY net loss $80.5M ($3.12/sh).
On August 8, 2024, the Company notified Christopher Degnan, the Company’s Chief Financial Officer and principal financial officer, that his position is being eliminated, effective August 31, 2024, in order to save costs as the Company moves forward with the dissolution of the Company, as described below.
On June 4, 2024, Galera Therapeutics, Inc. (the “Company”) notified Robert A. Beardsley, Ph.D., the Company’s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics.
On August 9, 2023, Mark Bachleda, Pharm.D., the Company’s Chief Commercial Officer, was informed that his position was being eliminated in connection with the Workforce Reduction.
Max materiality 0.95 · Median 0.70 · Most common event other_material